SMMT - Summit Therapeutics plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Summit Therapeutics plc

136a Eastern Avenue
Milton Park
Abingdon OX14 4SB
United Kingdom
44 12 3544 3939
http://www.summitplc.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees76

Key Executives

NameTitlePayExercisedYear Born
Mr. Glyn O. EdwardsCEO & Exec. Director831.03kN/A1956
Mr. Erik OstrowskiChief Financial Officer657.74kN/A1973
Prof. David RoblinCOO, Chief Medical Officer and Pres of R&D595.61kN/A1966
Prof. Kay DaviesCo-Founder, Chairman of Scientific Advisory Board and Scientific AdvisorN/AN/A1950
Ms. Michelle AveryDirector of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

Corporate Governance

Summit Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.